AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 21112774
Drug: Concurrent cycles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent cycles of cisplatin
Trial: 12657406
Drug: Aprotinin (1,000,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprotinin (1,000,000 KIU loading dose, followed by an infusion of 250,000 KIU/hr)
Trial: 10755072
Drug: Gold-standard definition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gold-standard definition of treatment superiority with unpublished scales
Trial: 1313717
Drug: Itraconazole 100
RxNorm normalized name: itraconazole 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itraconazole 100 mg o.d.
Trial: 1313717
Drug: Griseofulvin 500
RxNorm normalized name: griseofulvin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Griseofulvin 500 mg o.d.
Trial: 1313717
Drug: Itraconazole 100
RxNorm normalized name: itraconazole 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itraconazole 100 mg daily for 15 days (tinea corporis/cruris) and 30 days (tinea pedis/manus).
Trial: 1313717
Drug: Griseofulvin 500
RxNorm normalized name: griseofulvin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Griseofulvin 500 mg ultramicronized daily for 15 days (tinea corporis/cruris) and 30 days (tinea pedis/manus).
Trial: 1313717
Drug: Itraconazole 100
RxNorm normalized name: itraconazole 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itraconazole 100 mg daily.
Trial: 1313717
Drug: Griseofulvin 500
RxNorm normalized name: griseofulvin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Griseofulvin 500 mg daily.
Trial: 26088405
Drug: High-dose dimethylfumarate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose dimethylfumarate (DMF)
Trial: 25232107
Drug: Serotonin modulation
RxNorm normalized name: serotonin
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serotonin modulation through pharmaceutical intervention
Trial: 17093981
Drug: Atomoxetine (max
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atomoxetine (max 1.8 mg/kg/day, daily) for 6-8 weeks
Trial: 8576747
Drug: Pulsatile oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pulsatile oxytocin administration (boluses every 8 minutes)
Trial: 8576747
Drug: Continuous oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuous oxytocin administration (conventional continuous intravenous infusion)
Trial: 2131793
Drug: HBI (sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HBI (sequential hemibody radiation with vincristine and prednisone)
Trial: 773486
Drug: guanethidine and
RxNorm normalized name: guanethidine and diuretics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: guanethidine and oxprenolol combination
Trial: 26341358
Drug: Tele-rehabilitation intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tele-rehabilitation intervention for 3 months, exercise 5 days a week using an iPad-based system, weekly video-conferencing with tele-therapists
Trial: 24257410
Drug: Self-help app
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Self-help app based on acceptance and commitment therapy and mindfulness-based cognitive behavioural therapy
Trial: 21788542
Drug: Cranberry capsules,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cranberry capsules, 500 mg twice daily
Trial: 21788542
Drug: Trimethoprim-sulfamethoxazole (TMP-SMX),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethoprim-sulfamethoxazole (TMP-SMX), 480 mg once daily
Trial: 12639647
Drug: Placebo group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo group (no active treatment).
Trial: 10831274
Drug: UFT (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UFT (400 mg/day) administered orally for 7 days prior to surgery
Trial: 9386863
Drug: Mitoxantrone 12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mitoxantrone 12 mg/sqm day 1; fluorouracil 370 mg/sqm and L-folinic acid 100 mg/sqm days 1-3 administered every three weeks
Trial: 9386863
Drug: Prolonged 5FU/L-FA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged 5FU/L-FA schedule (5 days)
Trial: 3001519
Drug: Intranasal alpha
RxNorm normalized name: alpha tocopherol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal alpha 2-interferon (5 X 10(6) IU)
Trial: 25016303
Drug: WHELD intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: WHELD intervention (comprehensive staff training on person-centred care, activities, and psychotropic medication use)
Trial: 19618831
Drug: Lidocaine without
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine without infusion (Group IV)
Trial: 19618831
Drug: Lidocaine without
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine without infusion and restart infusion before propofol (Group VI)
Trial: 19618831
Drug: Saline without
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline without infusion (Group III)
Trial: 17888016
Drug: Implant-supported single-tooth
RxNorm normalized name: Sus scrofa tooth preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implant-supported single-tooth replacements with different augmentation procedures
Trial: 10223775
Drug: Test product
RxNorm normalized name: Patch test product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test product (200 mg carbamazepine tablet 3 times a day)
Trial: 10223775
Drug: Reference product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference product (200 mg carbamazepine tablet 3 times a day)
Trial: 8574859
Drug: Microwaved spinach
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microwaved spinach (150 g, 4.3 g dietary fibre)
Trial: 8574859
Drug: Microwaved spinach
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microwaved spinach (250 g, 7.2 g dietary fibre)
Trial: 721788
Drug: Prazepam in
RxNorm normalized name: Product containing prazepam in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prazepam in divided doses
Trial: 27757733
Drug: Spironolactone (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone (25 mg for 1 week, then 50 mg for 3 weeks, then eplerenone 50 mg for 1 month)
Trial: 27757733
Drug: Eplerenone (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eplerenone (25 mg for 1 week, then 50 mg for 3 weeks, then spironolactone 50 mg for 1 month)
Trial: 27757733
Drug: Placebo (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (1 tablet for 1 week, then 2 tablets for 3 weeks, then spironolactone 50 mg for 1 month)
Trial: 20737243
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg Cu/day (copper sulfate) for 2 months
Trial: 17691886
Drug: Combination cessation
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination cessation medications
Trial: 17691886
Drug: Behavioral counseling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral counseling and combination pharmacotherapy
Trial: 31257613
Drug: Camelina sativa
RxNorm normalized name: CAMELINA SATIVA WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Camelina sativa oil (CSO) providing 10 g/day alpha-linolenic acid (ALA)
Trial: 29273470
Drug: IsaGenesis soft
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IsaGenesis soft gel formulation
Trial: 29273470
Drug: Product B
RxNorm normalized name: Product base
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Product B powdered capsule
Trial: 26854478
Drug: Dialectical Behavior
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dialectical Behavior Therapy (DBT) for 16 weeks
Trial: 22298802
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral bolus of 600,000 IU vitamin D₃
Trial: 21146054
Drug: Unilateral spinal
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unilateral spinal anesthesia with 6 mg of hyperbaric or hypobaric bupivacaine (RQ group)
Trial: 21146054
Drug: Combined sciatic-femoral
RxNorm normalized name: Sus scrofa temporal lobe preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined sciatic-femoral nerve block with 800 mg of 1.6% lidocaine with epinephrine (CFI group)
Trial: 18020004
Drug: Local therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local therapy for low-risk tumours
Trial: 18020004
Drug: Brachytherapy and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brachytherapy and hormonal therapy
Trial: 16684855
Drug: Hormone Replacement
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone Replacement Therapy (HRT) - 0.625 mg conjugated estrogens + 2.5 mg medroxyprogesterone acetate (n = 9)
Trial: 15252820
Drug: Sertraline (50-150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (50-150 mg daily)
Trial: 15252820
Drug: Paroxetine (20-60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine (20-60 mg daily)
Trial: 15252820
Drug: Sertraline and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline and Paroxetine
Trial: 11119088
Drug: Immunohistochemistry using
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunohistochemistry using labelled antibody to vinculin
Trial: 25854019
Drug: Flunarizine hydrochloride
RxNorm normalized name: flunarizine hydrochloride
DrugBank: Flunarizine (DB04841)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunarizine hydrochloride capsules orally
Trial: 23970774
Drug: Self-administered paper-based
RxNorm normalized name: paper birch pollen extract
DrugBank: Betula papyrifera pollen (DB10831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-administered paper-based interview (SAPI)
Trial: 9494172
Drug: Surgical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical therapy for stroke prevention
Trial: 3463544
Drug: 1 X
RxNorm normalized name: Black Cohosh 1 X Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 X 400 mg enoxacin
Trial: 3463544
Drug: 1 X
RxNorm normalized name: Black Cohosh 1 X Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 X 3 g amoxicillin
Trial: 26500075
Drug: Cytoreductive surgery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) using 100 mg/m2 of cisplatin for 90 min
Trial: 24772619
Drug: Intraoperative intrapelvic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative intrapelvic chemotherapy with hyperthermia (cisplatin at a dose of 150 mg, duration 60 minutes, temperature 44-45 degrees C)
Trial: 24772619
Drug: Intraoperative intrapelvic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative intrapelvic chemotherapy with hyperthermia
Trial: 24772619
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no intraoperative intrapelvic chemotherapy with hyperthermia)
Trial: 18923067
Drug: MK-0777 (benzodiazepine-like
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-0777 (benzodiazepine-like agent with selective activity at GABA(A) receptors containing alpha(2) or alpha(3) subunits)
Trial: 9586597
Drug: Long-term medical
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term medical therapy for BPH
Trial: 7635032
Drug: Withdrawal of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Withdrawal of antiepileptic drugs
Trial: 779871
Drug: Conventional treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatments (transfusion support with or without androgens)
Trial: 30853517
Drug: ESP Group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ESP Group (n = 30) received ultrasound-guided bilateral ESP block with 0.25% bupivacaine 20 mL
Trial: 25280910
Drug: High contact
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High contact force (CF) ≥22 g
Trial: 25280910
Drug: Low contact
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low contact force (CF) <22 g
Trial: 21602718
Drug: Hydroxyurea (HU)
RxNorm normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyurea (HU) at a mean dose of 16 mg/kg/d
Trial: 11190708
Drug: Hydromorphone (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydromorphone (4 mg slow-release)
Trial: 1462022
Drug: Inhaled ipratropium
RxNorm normalized name: ipratropium Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled ipratropium bromide (320 micrograms day‐1)
Trial: 3882368
Drug: Self-monitoring of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-monitoring of blood glucose (SMBG) confirmed symptoms of hypoglycemia in all children and detected asymptomatic hypoglycemia (BG <= 40 mg/dl) in 11 children.
Trial: 29763609
Drug: Sequential use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential use of oxytocin following cervical ripening balloon expulsion
Trial: 28101753
Drug: Zolpidem combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolpidem combined with paroxetine (combined treatment group, n = 45)
Trial: 23761390
Drug: Escitalopram (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram (10 mg on days 1-3, 20 mg on days 4-24, 10 mg on days 25-28)
Trial: 16340629
Drug: Endoscopic hemoclip
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endoscopic hemoclip treatment
Trial: 10825787
Drug: Topical Mometasone
RxNorm normalized name: mometasone Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Mometasone Furoate
Trial: 6389909
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg of dihydroergotamine plus 5000 IU of sodium heparin (DHE 5000)
Trial: 6389909
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg of dihydroergotamine plus 2500 IU heparin (DHE 2500)
Trial: 6389909
Drug: 5000 IU
RxNorm normalized name: D 5000 IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5000 IU of heparin (HEP 5000)
Trial: 6389909
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg of dihydroergotamine (DHE 0.5)
Trial: 29089267
Drug: Bismuth-based therapy
RxNorm normalized name: bismuth
DrugBank: Bismuth cation (DB14572)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bismuth-based therapy (esomeprazole 20mg b.i.d and Pylera 3 tablets q.i.d)
Trial: 29089267
Drug: Concomitant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concomitant therapy (esomeprazole 20mg plus amoxicillin 1,000mg, clarithromycin 500mg and tinidazole 500mg, all b.i.d.)
Trial: 29089267
Drug: Sequential therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential therapy (esomeprazole 20mg plus amoxicillin 1,000mg for 5 days followed by esomeprazole 20mg plus clarithromycin 500mg and tinidazole 500mg for 5 days, all b.i.d.)
Trial: 24713367
Drug: 13-valent pneumococcal
RxNorm normalized name: Streptococcus pneumoniae serotype 14 capsular antigen diphtheria CRM197 protein conjugate vaccine
DrugBank: Streptococcus pneumoniae type 14 capsular polysaccharide diphtheria CRM197 protein conjugate antigen (DB10289)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 13-valent pneumococcal vaccine
Trial: 16864164
Drug: Adjuvant CMF-type
RxNorm normalized name: collagen type I
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant CMF-type chemotherapy (CT)
Trial: 14620302
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment controls (G3)
Trial: 1736548
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin and orbital radiotherapy (Group 1)
Trial: 1736548
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin alone (Group 2)
Trial: 6704502
Drug: TRM-HCT combination
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TRM-HCT combination tablets
Trial: 6704502
Drug: TRM-HCT combination
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TRM-HCT combination capsules
Trial: 6704502
Drug: TRM-HCT combination
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TRM-HCT combination product
Trial: 27780819
Drug: 4 g
RxNorm normalized name: CTX4 Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g of whey protein per hour (PULSE)
Trial: 27780819
Drug: 28 g
RxNorm normalized name: SM Syringe 28 g, 0.5cc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 28 g of whey protein at 0 h and 12 g of whey protein at 7 h postexercise (BOLUS)
Trial: 27780819
Drug: 4 g
RxNorm normalized name: CTX4 Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g of maltodextrin per hour (placebo)
Trial: 23618598
Drug: Cognitive Bias
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Bias Modification of Interpretations (CBM-I) training, administered by parents over three consecutive evenings
Trial: 16750207
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of testosterone undecanoate and estradiol valerate (2 mg daily)
Trial: 16750207
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (testosterone + estradiol)
Trial: 11158692
Drug: 4% cromolyn
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4% cromolyn cream
Trial: 9988054
Drug: Paroxetine up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine up to 50 mg/day (n = 55)
Trial: 9988054
Drug: Fluoxetine up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine up to 80 mg/day (n = 54)
Trial: 9988054
Drug: Paroxetine and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine and Fluoxetine
Trial: 8306736
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of AusP and conventional auscultation (ConA)
Trial: 2903059
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg cetirizine 2 HCl
Trial: 4436447
Drug: Oral cephradine
RxNorm normalized name: Cephradine
DrugBank: Cefradine (DB01333)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral cephradine (2 g) with probenecid (1 g)
Trial: 4436447
Drug: Intramuscular cephradine
RxNorm normalized name: Cephradine
DrugBank: Cefradine (DB01333)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular cephradine (1 or 2 g) with probenecid (1 g)
Trial: 4436447
Drug: Oral cephradine
RxNorm normalized name: Cephradine
DrugBank: Cefradine (DB01333)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral cephradine (500 mg) in fasting subjects
Trial: 4436447
Drug: Oral cephradine
RxNorm normalized name: Cephradine
DrugBank: Cefradine (DB01333)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral cephradine (500 mg) in fed subjects
Trial: 31337174
Drug: Epidural saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural saline infusion at 1 mL/second (slow speed, A group)
Trial: 31337174
Drug: Epidural saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural saline infusion at 3 mL/second (rapid speed, B group)
Trial: 24915562
Drug: S. boulardii
RxNorm normalized name: Lactobac. plantarum/S. boulardii/Pediococcus acidilactici 8 billion cell ORAL CAPSULE,DELAYED RELEASE (ENTERIC COATED)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S. boulardii 125 mg every 12 hours during phototherapy
Trial: 22336311
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose pituitrin (0.01 - 0.03 U/min) added to conventional treatment
Trial: 22336311
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (antibiotics, fluid resuscitation, glucocorticoids, organ support, dopamine 1-15 µg/(kg·min), norepinephrine 0.5-2 µg/(kg·min))
Trial: 12759489
Drug: Omalizumab (0.016
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omalizumab (0.016 mg/kg/IgE every 4 weeks)
Trial: 27886247
Drug: Moxibustion (MG,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxibustion (MG, n=15)
Trial: 19755414
Drug: Telithromycin (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telithromycin (800 mg for 4 days)
Trial: 16958712
Drug: Maternal/social role
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maternal/social role preparation
Trial: 12515132
Drug: Intraperitoneal chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal chemotherapy (once, 48 hours before operation)
Trial: 12515132
Drug: Intraperitoneal chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal chemotherapy (twice, 96 hours and 48 hours before operation)